Summary

Syphilis Immunoassay Diagnostics Market – Scope of Report
TMR’s report on the global syphilis immunoassay diagnostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global syphilis immunoassay diagnostics market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global syphilis immunoassay diagnostics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the syphilis immunoassay diagnostics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global syphilis immunoassay diagnostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global syphilis immunoassay diagnostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global syphilis immunoassay diagnostics market.

The report delves into the competitive landscape of the global syphilis immunoassay diagnostics market. Key players operating in the global syphilis immunoassay diagnostics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global syphilis immunoassay diagnostics market profiled in this report.

Key Questions Answered in Global syphilis immunoassay diagnostics Market Report
• What is the sales/revenue generated by syphilis immunoassay diagnostics across all regions during the forecast period?
• What are the opportunities in the global syphilis immunoassay diagnostics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Syphilis Immunoassay Diagnostics Market – Research Objectives and Research Approach
The comprehensive report on the global syphilis immunoassay diagnostics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global syphilis immunoassay diagnostics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global syphilis immunoassay diagnostics market.

ページTOPに戻る

Table of Contents

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Syphilis Immunoassay Diagnostics Market
4. Market Overview
    4.1. Introduction
        4.1.1. Segment Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Syphilis Immunoassay Diagnostics Market Analysis and Forecasts, 2020-2034
        4.4.1. Market Revenue Projections (US$ Mn)
        4.4.2. Market Volume/Unit Shipments Projections
    4.5. Porter’s Five Force Analysis
5. Key Insights
    5.1. Key Industry Events
    5.2. Distributors Landscape
    5.3. PORTER’s Five Forces Analysis
    5.4. End-user Preference
    5.5. Epidemiology of Syphilis by Region/Countries
    5.6. Government Initiatives by Region/Countries
    5.7. Healthcare Expenditure by Region/Country (Health spending Total, US dollars/capita, 2022)
    5.8. PESTEL Analysis
    5.9. Impact of near patient testing and POC on syphilis market dynamics
    5.10. Brand and Pricing Analysis
    5.11. Regulatory Scenario by Region/ Country
    5.12. Supply Chain Analysis
    5.13. Technological Advancements
6. Global Syphilis Immunoassay Diagnostics Market Analysis and Forecasts, By Product
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast By Product, 2020-2034
        6.3.1. Analyzer
        6.3.2. Kits & Reagents
    6.4. Market Attractiveness By Product
7. Global Syphilis Immunoassay Diagnostics Market Analysis and Forecasts, By Technology
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast By Technology, 2020-2034
        7.3.1. Chemiluminescence Assay (CLIA)
        7.3.2. Enzyme Linked Immunosorbent Assay (ELISA
        7.3.3. Immunochromatographic Assay /Lateral Flow Assay
        7.3.4. Treponema pallidum latex agglutination (TPLA)
        7.3.5. Non-treponemal Flocculation Assay
    7.4. Market Attractiveness By Technology
8. Global Syphilis Immunoassay Diagnostics Market Analysis and Forecasts, By Test Type
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast By Test Type, 2020-2034
        8.3.1. Treponemal Tests
        8.3.2. Non-Treponemal Tests
    8.4. Market Attractiveness By Test Type
9. Global Syphilis Immunoassay Diagnostics Market Analysis and Forecasts, By Location of Testing
    9.1. Introduction & Definition
    9.2. Key Findings / Developments
    9.3. Market Value Forecast By Location of Testing, 2020-2034
        9.3.1. Point-of-care testing (POCT)
        9.3.2. Patient Self-Tests (PST)
        9.3.3. Clinical Settings
    9.4. Market Attractiveness By Location of Testing
10. Global Syphilis Immunoassay Diagnostics Market Analysis and Forecasts, By End-user
    10.1. Introduction & Definition
    10.2. Key Findings / Developments
    10.3. Market Value Forecast By End-user, 2020-2034
        10.3.1. Hospitals and Clinics
        10.3.2. Diagnostics Laboratories
        10.3.3. Home Care
        10.3.4. Public Health Laboratory
        10.3.5. Others
    10.4. Market Attractiveness By End-user
11. Global Syphilis Immunoassay Diagnostics Market Analysis and Forecasts, By Region
    11.1. Key Findings
    11.2. Market Value Forecast By Region
        11.2.1. North America
        11.2.2. Europe
        11.2.3. Asia Pacific
        11.2.4. Latin America
        11.2.5. Middle East & Africa
    11.3. Market Attractiveness By Country/Region
12. North America Syphilis Immunoassay Diagnostics Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast By Product, 2020-2034
        12.2.1. Analyzer
        12.2.2. Kits & Reagents
    12.3. Market Value Forecast By Technology, 2020-2034
        12.3.1. Chemiluminescence Assay (CLIA)
        12.3.2. Enzyme Linked Immunosorbent Assay (ELISA
        12.3.3. Immunochromatographic Assay /Lateral Flow Assay
        12.3.4. Treponema pallidum latex agglutination (TPLA)
        12.3.5. Non-treponemal Flocculation Assay
    12.4. Market Value Forecast By Test Type, 2020-2034
        12.4.1. Treponemal Tests
        12.4.2. Non-Treponemal Tests
    12.5. Market Value Forecast By Location of Testing, 2020-2034
        12.5.1. Point-of-care testing (POCT)
        12.5.2. Patient Self-Tests (PST)
        12.5.3. Clinical Settings
    12.6. Market Value Forecast By End-user, 2020-2034
        12.6.1. Hospitals and Clinics
        12.6.2. Diagnostics Laboratories
        12.6.3. Home Care
        12.6.4. Public Health Laboratory
        12.6.5. Others
    12.7. Market Value Forecast By Country, 2020-2034
        12.7.1. U.S.
        12.7.2. Canada
    12.8. Market Attractiveness Analysis
        12.8.1. By Product
        12.8.2. By Technology
        12.8.3. By Test Type
        12.8.4. By Location of Testing
        12.8.5. By End-user
        12.8.6. By Country
13. Europe Syphilis Immunoassay Diagnostics Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast By Product, 2020-2034
        13.2.1. Analyzer
        13.2.2. Kits & Reagents
    13.3. Market Value Forecast By Technology, 2020-2034
        13.3.1. Chemiluminescence Assay (CLIA)
        13.3.2. Enzyme Linked Immunosorbent Assay (ELISA
        13.3.3. Immunochromatographic Assay /Lateral Flow Assay
        13.3.4. Treponema pallidum latex agglutination (TPLA)
        13.3.5. Non-treponemal Flocculation Assay
    13.4. Market Value Forecast By Test Type, 2020-2034
        13.4.1. Treponemal Tests
        13.4.2. Non-Treponemal Tests
    13.5. Market Value Forecast By Location of Testing, 2020-2034
        13.5.1. Point-of-care testing (POCT)
        13.5.2. Patient Self-Tests (PST)
        13.5.3. Clinical Settings
    13.6. Market Value Forecast By End-user, 2020-2034
        13.6.1. Hospitals and Clinics
        13.6.2. Diagnostics Laboratories
        13.6.3. Home Care
        13.6.4. Public Health Laboratory
        13.6.5. Others
    13.7. Market Value Forecast By Country, 2020-2034
        13.7.1. Germany
        13.7.2. U.K.
        13.7.3. France
        13.7.4. Italy
        13.7.5. Spain
        13.7.6. Rest of Europe
    13.8. Market Attractiveness Analysis
        13.8.1. By Product
        13.8.2. By Technology
        13.8.3. By Test Type
        13.8.4. By Location of Testing
        13.8.5. By End-user
        13.8.6. By Country
14. Asia Pacific Syphilis Immunoassay Diagnostics Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast By Product, 2020-2034
        14.2.1. Analyzer
        14.2.2. Kits & Reagents
    14.3. Market Value Forecast By Technology, 2020-2034
        14.3.1. Chemiluminescence Assay (CLIA)
        14.3.2. Enzyme Linked Immunosorbent Assay (ELISA
        14.3.3. Immunochromatographic Assay /Lateral Flow Assay
        14.3.4. Treponema pallidum latex agglutination (TPLA)
        14.3.5. Non-treponemal Flocculation Assay
    14.4. Market Value Forecast By Test Type, 2020-2034
        14.4.1. Treponemal Tests
        14.4.2. Non-Treponemal Tests
    14.5. Market Value Forecast By Location of Testing, 2020-2034
        14.5.1. Point-of-care testing (POCT)
        14.5.2. Patient Self-Tests (PST)
        14.5.3. Clinical Settings
    14.6. Market Value Forecast By End-user, 2020-2034
        14.6.1. Hospitals and Clinics
        14.6.2. Diagnostics Laboratories
        14.6.3. Home Care
        14.6.4. Public Health Laboratory
        14.6.5. Others
    14.7. Market Value Forecast By Country, 2020-2034
        14.7.1. China
        14.7.2. Japan
        14.7.3. India
        14.7.4. Australia & New Zealand
        14.7.5. Rest of Asia Pacific
    14.8. Market Attractiveness Analysis
        14.8.1. By Product
        14.8.2. By Technology
        14.8.3. By Test Type
        14.8.4. By Location of Testing
        14.8.5. By End-user
        14.8.6. By Country
15. Latin America Syphilis Immunoassay Diagnostics Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast By Product, 2020-2034
        15.2.1. Analyzer
        15.2.2. Kits & Reagents
    15.3. Market Value Forecast By Technology, 2020-2034
        15.3.1. Chemiluminescence Assay (CLIA)
        15.3.2. Enzyme Linked Immunosorbent Assay (ELISA
        15.3.3. Immunochromatographic Assay /Lateral Flow Assay
        15.3.4. Treponema pallidum latex agglutination (TPLA)
        15.3.5. Non-treponemal Flocculation Assay
    15.4. Market Value Forecast By Test Type, 2020-2034
        15.4.1. Treponemal Tests
        15.4.2. Non-Treponemal Tests
    15.5. Market Value Forecast By Location of Testing, 2020-2034
        15.5.1. Point-of-care testing (POCT)
        15.5.2. Patient Self-Tests (PST)
        15.5.3. Clinical Settings
    15.6. Market Value Forecast By End-user, 2020-2034
        15.6.1. Hospitals and Clinics
        15.6.2. Diagnostics Laboratories
        15.6.3. Home Care
        15.6.4. Public Health Laboratory
        15.6.5. Others
    15.7. Market Value Forecast By Country, 2020-2034
        15.7.1. Brazil
        15.7.2. Mexico
        15.7.3. Rest of Latin America
    15.8. Market Attractiveness Analysis
        15.8.1. By Product
        15.8.2. By Technology
        15.8.3. By Test Type
        15.8.4. By Location of Testing
        15.8.5. By End-user
        15.8.6. By Country
16. Middle East & Africa Syphilis Immunoassay Diagnostics Market Analysis and Forecast
    16.1. Introduction
        16.1.1. Key Findings
    16.2. Market Value Forecast By Product, 2020-2034
        16.2.1. Analyzer
        16.2.2. Kits & Reagents
    16.3. Market Value Forecast By Technology, 2020-2034
        16.3.1. Chemiluminescence Assay (CLIA)
        16.3.2. Enzyme Linked Immunosorbent Assay (ELISA
        16.3.3. Immunochromatographic Assay /Lateral Flow Assay
        16.3.4. Treponema pallidum latex agglutination (TPLA)
        16.3.5. Non-treponemal Flocculation Assay
    16.4. Market Value Forecast By Test Type, 2020-2034
        16.4.1. Treponemal Tests
        16.4.2. Non-Treponemal Tests
    16.5. Market Value Forecast By Location of Testing, 2020-2034
        16.5.1. Point-of-care testing (POCT)
        16.5.2. Patient Self-Tests (PST)
        16.5.3. Clinical Settings
    16.6. Market Value Forecast By End-user, 2020-2034
        16.6.1. Hospitals and Clinics
        16.6.2. Diagnostics Laboratories
        16.6.3. Home Care
        16.6.4. Public Health Laboratory
        16.6.5. Others
    16.7. Market Value Forecast By Country, 2020-2034
        16.7.1. GCC Countries
        16.7.2. South Africa
        16.7.3. Rest of Middle East & Africa
    16.8. Market Attractiveness Analysis
        16.8.1. By Product
        16.8.2. By Technology
        16.8.3. By Test Type
        16.8.4. By Location of Testing
        16.8.5. By End-user
        16.8.6. By Country
17. Competition Landscape
    17.1. Market Player - Competition Matrix (By Tier and Size of companies)
    17.2. Market Share Analysis, by Company (2023)
    17.3. Company Profiles
        17.3.1. Abbott
            17.3.1.1. Company Overview
            17.3.1.2. Financial Overview
            17.3.1.3. Product Portfolio
            17.3.1.4. Business Strategies
            17.3.1.5. Recent Developments
        17.3.2. Becton, Dickinson, and Company (BD)
            17.3.2.1. Company Overview
            17.3.2.2. Financial Overview
            17.3.2.3. Product Portfolio
            17.3.2.4. Business Strategies
            17.3.2.5. Recent Developments
        17.3.3. bioMérieux SA
            17.3.3.1. Company Overview
            17.3.3.2. Financial Overview
            17.3.3.3. Product Portfolio
            17.3.3.4. Business Strategies
            17.3.3.5. Recent Developments
        17.3.4. Bio-Rad Laboratories, Inc
            17.3.4.1. Company Overview
            17.3.4.2. Financial Overview
            17.3.4.3. Product Portfolio
            17.3.4.4. Business Strategies
            17.3.4.5. Recent Developments
        17.3.5. Chembio Diagnostics, Inc.
            17.3.5.1. Company Overview
            17.3.5.2. Financial Overview
            17.3.5.3. Product Portfolio
            17.3.5.4. Business Strategies
            17.3.5.5. Recent Developments
        17.3.6. Danaher Corporation
            17.3.6.1. Company Overview
            17.3.6.2. Financial Overview
            17.3.6.3. Product Portfolio
            17.3.6.4. Business Strategies
            17.3.6.5. Recent Developments
        17.3.7. DiaSorin S.p.A.
            17.3.7.1. Company Overview
            17.3.7.2. Financial Overview
            17.3.7.3. Product Portfolio
            17.3.7.4. Business Strategies
            17.3.7.5. Recent Developments
        17.3.8. Roche Diagnostics (F. Hoffmann-La Roche AG)
            17.3.8.1. Company Overview
            17.3.8.2. Financial Overview
            17.3.8.3. Product Portfolio
            17.3.8.4. Business Strategies
            17.3.8.5. Recent Developments
        17.3.9. Fujirebio
            17.3.9.1. Company Overview
            17.3.9.2. Financial Overview
            17.3.9.3. Product Portfolio
            17.3.9.4. Business Strategies
            17.3.9.5. Recent Developments
        17.3.10. QuidelOrtho Corporation
            17.3.10.1. Company Overview
            17.3.10.2. Financial Overview
            17.3.10.3. Product Portfolio
            17.3.10.4. Business Strategies
            17.3.10.5. Recent Developments
        17.3.11. Shenzhen New Industries Biomedical Engineering Co., Ltd.
            17.3.11.1. Company Overview
            17.3.11.2. Financial Overview
            17.3.11.3. Product Portfolio
            17.3.11.4. Business Strategies
            17.3.11.5. Recent Developments
        17.3.12. Siemens Healthineers AG
            17.3.12.1. Company Overview
            17.3.12.2. Financial Overview
            17.3.12.3. Product Portfolio
            17.3.12.4. Business Strategies
            17.3.12.5. Recent Developments
        17.3.13. Sekisui Chemical Co Ltd
            17.3.13.1. Company Overview
            17.3.13.2. Financial Overview
            17.3.13.3. Product Portfolio
            17.3.13.4. Business Strategies
            17.3.13.5. Recent Developments
        17.3.14. Thermo Fisher Scientific, Inc.
            17.3.14.1. Company Overview
            17.3.14.2. Financial Overview
            17.3.14.3. Product Portfolio
            17.3.14.4. Business Strategies
            17.3.14.5. Recent Developments
        17.3.15. Trinity Biotech
            17.3.15.1. Company Overview
            17.3.15.2. Financial Overview
            17.3.15.3. Product Portfolio
            17.3.15.4. Business Strategies
            17.3.15.5. Recent Developments